I. Matériel, M. , I. Résultats, and .. , 27 B. Population étudiée28 C. Analyse statistique, 33 B. Caractéristiques des populations de la Réunion et de métropole, p.38

A. Go, E. Hylek, and K. Phillips, Prevalence of Diagnosed Atrial Fibrillation in Adults, JAMA, vol.285, issue.18, pp.2370-2375, 2001.
DOI : 10.1001/jama.285.18.2370

A. Camm, P. Kirchhof, and G. Lip, Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA), Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), European Heart Journal, vol.31, pp.2369-429, 2010.

P. Wolf, R. Abbott, and W. Kannel, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke, vol.22, issue.8, pp.983-991, 1991.
DOI : 10.1161/01.STR.22.8.983

H. Autorité and D. Santé, HAS) Bon usage du médicament. Fibrillation auriculaire non valvulaire. Quelle place pour les anticoagulant oraux non AVK, 2013.

R. Pisters, D. Lane, R. Nieuwlaat, C. De-vos, H. Crijns et al., A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation, Chest, vol.138, issue.5, pp.1093-100, 2010.
DOI : 10.1378/chest.10-0134

. Groupe-d-'etude-sur-l-'hémostase and . La-thrombose, Recommandations professionnelles rédigées avec la participation méthodologique de la Haute Autorité de Santé (HAS): Prise en charge des surdosages en antivitamines K, des situations à risque hémorragique et des accidents hémorragiques chez les patients traités par antivitamines K en ville et en milieu hospitalier, GEHT et HAS Avril STV, vol.20, pp.1-104, 2008.

C. Van-walraven, A. Jennings, and N. Oake, Effect of Study Setting on Anticoagulation Control, Chest, vol.129, issue.5, pp.1155-66, 2006.
DOI : 10.1378/chest.129.5.1155

S. Laporte, S. Quenet, and A. Buchmuller-cordier, Compliance and stabi-lity of INR of two oral anticoagulants with different half-lives : a rando-mised trial, Thromb Haemost, vol.89, pp.458-67, 2003.

G. Palareti, C. Legnani, and G. Guazzaloca, Risks factors for highly unstable response to oral anticoagulation: a case-control study, British Journal of Haematology, vol.87, issue.1, pp.72-80, 2005.
DOI : 10.1345/aph.1A198

A. Gadisseur, F. Van-der-meer, and H. Adriaansen, Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon, British Journal of Haematology, vol.7, issue.4, pp.940-946, 2002.
DOI : 10.1046/j.1365-2141.2002.03493.x

L. Bodin and M. Loriot, La pharmacogénétique : application aux anticoagulants oraux. STV, 2003.

H. Xie, H. Prasad, R. Kim, and C. Stein, CYP2C9 allelic variants: ethnic distribution and functional significance, Advanced Drug Delivery Reviews, vol.54, issue.10, pp.1257-70, 2002.
DOI : 10.1016/S0169-409X(02)00076-5

H. Furuya, P. Fernandez-salguero, and W. Gregory, Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose require-ment in patients undergoing anticoagulation therapy

G. Aithal, C. Day, P. Kesteven, and A. Daly, Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, The Lancet, vol.353, issue.9154, pp.717-726, 1999.
DOI : 10.1016/S0140-6736(98)04474-2

M. Higashi, D. Veenstra, and L. Kondo, Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy, JAMA, vol.287, issue.13, pp.1690-1698, 2002.
DOI : 10.1001/jama.287.13.1690

R. Loebstein, H. Yonath, and D. Peleg, Interindividual variability in sensitivity to warfarin-Nature or nurture?, Clinical Pharmacology & Therapeutics, vol.70, issue.2, pp.159-64, 2001.
DOI : 10.1067/mcp.2001.117444

M. Margaglione, D. Colaizzo, D. 'andrea, and G. , Genetic modulation of oral anticoagulation with warfarin, Thromb Haemost, vol.84, pp.775-783, 2000.

J. Taube, D. Halsall, and T. Baglin, Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment, Blood, vol.96, pp.1816-1825, 2000.

J. Lindh, L. Holm, M. Andersson, and A. Rane, Influence of CYP2C9 genotype on warfarin dose requirements???a systematic review and meta-analysis, European Journal of Clinical Pharmacology, vol.7, issue.4, pp.365-75, 2009.
DOI : 10.1007/s00228-008-0584-5

C. Moreau, E. Pautas, C. Duverlie, C. Berndt, and M. Andro, A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone, Thrombosis and Haemostasis, vol.111, issue.4, 2013.
DOI : 10.1160/TH13-07-0555

URL : https://hal.archives-ouvertes.fr/hal-00935340

S. Kimmel, Z. Chen, and M. Price, The Influence of Patient Adherence on Anticoagulation Control With Warfarin, Archives of Internal Medicine, vol.167, issue.3, pp.229-264, 2007.
DOI : 10.1001/archinte.167.3.229

E. Rombouts, F. Rosendaal, and F. Van-der-meer, Daily vitamin K supplementation improves anticoagulant stability, Journal of Thrombosis and Haemostasis, vol.148, issue.10, pp.2043-2051, 2007.
DOI : 10.1136/bmj.329.7456.15

G. Palareti, C. Legnani, and G. Guazzaloca, Risks factors for highly unstable response to oral anticoagulation: a case-control study, British Journal of Haematology, vol.87, issue.1, pp.72-80, 2005.
DOI : 10.1345/aph.1A198

S. Kumar, J. Haigh, and L. Rhodes, Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy, Thromb Haemost, vol.62, pp.729-761, 1989.

R. Beyth, L. Quinn, and C. Landefeld, A Multicomponent Intervention To Prevent Major Bleeding Complications in Older Patients Receiving Warfarin, Annals of Internal Medicine, vol.133, issue.9, pp.687-95, 2000.
DOI : 10.7326/0003-4819-133-9-200011070-00010

T. Khan, F. Kamali, and P. Kesteven, The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation, British Journal of Haematology, vol.26, issue.4, pp.557-64, 2004.
DOI : 10.1016/S0002-9343(98)00389-1

G. Hanania, Management of anticoagulants during pregnancy, Heart, vol.86, issue.2, pp.125-131, 2001.
DOI : 10.1136/heart.86.2.125

L. Wickramasinghe, S. Basu, and S. Bansal, LONG-TERM ORAL ANTICOAGULANT THERAPY IN ELDERLY PATIENTS, Age and Ageing, vol.17, issue.6, pp.388-96, 1988.
DOI : 10.1093/ageing/17.6.388

. Spirit-study and . Group, A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin, Annals of Neurology, vol.76, issue.6, pp.857-65, 1997.
DOI : 10.1002/ana.410420606

E. Smith, J. Rosand, and K. Knudsen, Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke, Neurology, vol.59, issue.2, pp.193-200, 2002.
DOI : 10.1212/WNL.59.2.193

V. Franco, C. Polanczyk, and N. Clausell, Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols, The American Journal of Medicine, vol.116, issue.10, pp.651-657, 2004.
DOI : 10.1016/j.amjmed.2003.12.036

E. Sconce, T. Khan, and J. Mason, Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation, Thrombosis and Haemostasis, vol.93, pp.872-877, 2005.
DOI : 10.1160/TH04-12-0773

A. Nationale-de-la, Sécurité du Médicament et des produits de santé (ANSM) Vous et votre traitement par AVK. Carnet d'information et de suivi du traitement, ANSM. Février, 2013.

H. Janice and E. , Interactions with dietary factors with anticoagulant Journal of the American Dietetary Association, 1995.

C. Landefeld, E. Cook, and M. Flatley, Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy, The American Journal of Medicine, vol.82, issue.4, pp.703-716, 1987.
DOI : 10.1016/0002-9343(87)90004-0

C. Landefeld, P. Anderson, and L. Goodnough, The bleeding severity index: Validation and comparison to other methods for classifying bleeding complications of medical therapy, Journal of Clinical Epidemiology, vol.42, issue.8, pp.711-719, 1989.
DOI : 10.1016/0895-4356(89)90066-8

S. Fihn, M. Mcdonell, and D. Martin, Risk Factors for Complications of Chronic Anticoagulation: A Multicenter Study, Annals of Internal Medicine, vol.118, issue.7, pp.511-531, 1993.
DOI : 10.7326/0003-4819-118-7-199304010-00005

G. Palareti, J. Hirsh, and C. Legnani, Oral Anticoagulation Treatment in the Elderly, Archives of Internal Medicine, vol.160, issue.4, pp.470-478, 2000.
DOI : 10.1001/archinte.160.4.470

V. Pengo, C. Legnani, and F. Noventa, Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multi-center Inception Cohort Study, Thromb Haemost, vol.85, pp.418-440, 2001.

S. Schulman and C. Kearon, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients, Journal of Thrombosis and Haemostasis, vol.1, issue.4, pp.692-696, 2005.
DOI : 10.1111/j.1538-7836.2005.01204.x

C. Landefeld, M. Rosenblatt, and O. Goldman, Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. The American journal of medicine, pp.153-59, 1989.

C. Landefeld and O. Goldman, Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. The American journal of medicine, pp.144-52, 1989.

C. Landefeld and R. Beyth, Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. The American journal of medicine, pp.315-343, 1993.

M. Ezekowitz, S. Bridgers, K. James, N. Carliner, C. Colling et al., Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation, New England Journal of Medicine, vol.327, issue.20, pp.1406-1418, 1992.
DOI : 10.1056/NEJM199211123272002

A. Gulløv, B. Koefoed, and P. Petersen, Bleeding During Warfarin and Aspirin Therapy in Patients With Atrial Fibrillation, Archives of Internal Medicine, vol.159, issue.12, pp.1322-1330, 1999.
DOI : 10.1001/archinte.159.12.1322

T. Yamaguchi, Optimal Intensity of Warfarin Therapy for Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation : A Multicenter, Prospective, Randomized Trial, Stroke, vol.31, issue.4
DOI : 10.1161/01.STR.31.4.817

J. Van-der-heijden, B. Rekke, B. Hutten, F. Van-der-meer, M. Remkes et al., Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX, Journal of Thrombosis and Haemostasis, vol.85, issue.7, pp.1104-1113, 2004.
DOI : 10.1111/j.1538-7836.2004.00768.x

J. Douketis, K. Arneklev, S. Goldhaber, J. Spandorfer, F. Halperin et al., Comparison of Bleeding in Patients With Nonvalvular Atrial Fibrillation Treated With Ximelagatran or Warfarin, Archives of Internal Medicine, vol.166, issue.8, pp.853-862, 2006.
DOI : 10.1001/archinte.166.8.853

F. Cotté, G. Chaize, I. Kachaner, A. Gaudin, A. Vainchtock et al., Incidence and Cost of Stroke and Hemorrhage in Patients Diagnosed with Atrial Fibrillation in France, Journal of Stroke and Cerebrovascular Diseases, vol.23, issue.2, 2013.
DOI : 10.1016/j.jstrokecerebrovasdis.2013.08.022

R. Lavergne, Le grand livre des tisaneurs et plantes médicinales indigènes de la Réunion

D. Vaxelaire, Le grand livre de l'histoire de la Réunion de 1848 à l'an, 2000.

D. Vaxelaire, Le grand livre de l

L. Labache and . L-'ethnicité-chez-les-jeunes-réunionnais, L'ethnicit?? chez les jeunes R??unionnais, Agora d??bats/jeunesses, vol.9, issue.1, pp.94-104, 1997.
DOI : 10.3406/agora.1997.1133

L. L. Labache, ethnicité chez les Réunionnais en migration, Hermès, pp.32-33, 1988.

O. Régionale-de and L. Santé, La précarité à la Réunion, Formation et scolarité

. Tableau-de-bord, disponible sur le site ors-réunion.org, ORS. Mars, issue.6, 2010.

C. Patrice, Le Cari partagé : anthropologie de l'alimentation à l'ile de la Réunion Paris, 2000.

L. Tibère, Manger créole. L'alimentation dans les constructions identitaires à la Réunion

M. Bepari, P. Maity, B. Sinha, and S. Choudhury, Eupatorium Ayapana Leaf Extracts Enhance Antioxidant Potential In Ehrlich's Ascites Carcinoma-Bearing Swiss Albino Mice, International Journal of Life Science & Pharma Research, vol.4, issue.3, 2013.

O. Régionale-de and L. Santé, Les maladies de l'appareil circulatoire à La Réunion

. Tableau-de-bord and . Ors, Décembre 2011.(disponible sur le site ors-réunion.org)

M. Païta and A. Weill, Les personnes en affection de longue durée au 31 décembre 2008. Points de repère, CNAMTS, issue.27, 2009.

L. Maladie, Répartition et taux pour les principales maladies (CIM-10) des personnes en affection de longue durée (ALD 30 ou 31) au 31 décembre 2012 pour le régime général (population prévalente), caractéristiques d'age et de sexe, Tableau III. L'Assurance maladie

O. Régionale-de and L. Santé, Les maladies vasculaires cérébrales à La Réunion

. Tableau-de-bord, . Ors, and . Mai, disponible sur le site ors-réunion.org, 2013.

L. Huiart, P. Ernst, and S. Suissa, Cardiovascular Morbidity and Mortality in COPD, Chest, vol.128, issue.4, pp.2640-2646, 2005.
DOI : 10.1378/chest.128.4.2640

J. A. Delaney, Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding, Canadian Medical Association Journal, vol.177, issue.4, pp.347-51, 2007.
DOI : 10.1503/cmaj.070186

V. Valkhoff, P. Coloma, G. Masclee, R. Gini, F. Innocenti et al., Validation study in four health-care databases: upper gastrointestinal bleeding misclassification affects precision but not magnitude of drug-related upper gastrointestinal bleeding risk, Journal of Clinical Epidemiology, vol.67, issue.8
DOI : 10.1016/j.jclinepi.2014.02.020

O. Régionale-de and L. Santé, Le diabète à La Réunion

O. Régionale-de and L. Santé, Les addictions à La Réunion. Synthèse des résultats par produits

O. Régionale-de and L. Santé, Les addictions à La Réunion

. Tableau-de-bord and . Ors, Novembre 2013.(disponible sur le site ors-réunion.org)

A. Charlemagne, J. Blacher, A. Cohen, J. Collet, F. Diévart et al., Epidemiology of atrial fibrillation in France: Extrapolation of international epidemiological data to France and analysis of French hospitalization data. Archives of Cardiovascular Diseases, pp.115-139, 2011.

P. Sabouret, C. Willems, F. Cotté, M. P. Mercier, F. Depret-bixio et al., PCV17 A Cross-Sectional Assessment of Atrial Fibrillation Management Among French Patients in Primary Care, Value in Health, vol.15, issue.7
DOI : 10.1016/j.jval.2012.08.960